A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy

Breast Cancer Research and Treatment

Volumn 148, Issue 1, 2014, Pages 107-116

  Buchner, Anton ^a   Elsässer, Reiner ^a   Bias, Peter ^a  

^a Ratiopharm   (Germany)

Author keywords

Breast cancer; Granulocyte colony stimulating factor; Lipegfilgrastim; Neutropenia; Phase 2 clinical trial

Indexed keywords

DOCETAXEL; DOXORUBICIN; LIPEGFILGRASTIM; PEGFILGRASTIM; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; TAXOID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; CONVALESCENCE; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; SINGLE DRUG DOSE; YOUNG ADULT; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; RECOMBINANT PROTEINS; TAXOIDS;

EID: 84921936469     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3120-6     Document Type: Article

References (22)

1. Holmes FA, O’Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727–731
2. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, The European Organisation for Research and Treatment of Cancer (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32
3. Page AV, Liles WC (2011) Colony-stimulating factors in the prevention and management of infectious diseases. Infect Dis Clin N Am 25:803–817
4. NCCN Clinical Practice Guidelines in Oncology. Myeloid Growth Factors v.2.2013 (2013) Fort Washington, PA: National Comprehensive Cancer Network. Available at: www.nccn.org. Accessed 28 May 2014
5. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based, clinical practice guideline. J Clin Oncol 24:3187–3205
6. Gascon P (2012) Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol 7(suppl 1):S29–S34
7. Yang BB, Kido A (2011) Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokin 50:295–306
8. von Minckwitz G, Schwenkglenks M, Skacel T, Lyman GH, Pousa AL, Bacon P, Easton V, Aapro MS (2009) Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management: results from an integrated analysis. Eur J Cancer 45:608–617
9. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ, The International Pegfilgrastim 749 Study Group (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29–35
10. Lonquex: Summary of Product Characteristics. London: European Medicines Agency; 2013
11. Bondarenko I, Bias P, Elsasser R, Buchner A (2013) Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies [poster P162]. Presented at: Biennial European Multidisciplinary Cancer Congress, Amsterdam, The Netherlands, September 27–October 1, 2013
12. De Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F, The ESMO Guidelines Working Group (2010) Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 21(suppl 5):v252–v256
13. European Medicines Agency (2007) Guideline on clinical trials with haematopoietic growth factors for the prophylaxis of infection following myelosuppressive or myeloablative therapy. EMEA/CPMO/555/95 Rev. 1. Available at: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/12/WC500017738.pdf. Accessed 28 May 2014
14. Edge S, Byrd, Compton CC, Fritz AG, Greene FL, Trotti A (2011) AJCC cancer staging manual, 7th edn. Springer, New York
15. del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H (2008) XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 8:332–338
16. Holmes FA, Jones SE, O’Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13:903–909
17. Brain EG, Bachelot T, Serin D, Kirscher S, Graic Y, Eymard JC, Extra JM, Combe M, Fourme E, Noguès C, Rouëssé J, The RAPP-01 Trial Investigators (2005) Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA 293:2367–2371
18. Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178–1184
19. Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404
20. Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 23:2283–2295
21. Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J (2011) Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin 27:79–86
22. Engert A, delGiglio A, Bias P, Lubenau H, Gatzemeier U, Heigener D (2009) Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin’s lymphoma. Onkologie 32:599–604